Shanghai Lixiang Pharmaceutical

Shanghai Lixiang Pharmaceutical is a clinical-stage biotechnology company based in China, specializing in the development of innovative small molecule therapeutics for metabolic diseases. The company's primary focus is on the discovery and advancement of oral agonists targeting the GLP-1, GIP, and Glucagon receptors to treat conditions such as type 2 diabetes and obesity. Their lead candidate, LX-001, is a potent, orally available GLP-1 receptor agonist currently undergoing clinical evaluation. By leveraging expertise in medicinal chemistry, the company aims to provide more convenient and effective treatment options compared to traditional injectable biologics in the metabolic space.